Key result
Ticagrelor reduces major cardiovascular events ~16% vs clopidogrel in ACS.
Why the study?
ACS remains among the foremost causes of cardiovascular mortality worldwide, motivating a comprehensive, evidence-based appraisal of ticagrelor pharmacology, clinical efficacy, safety, and decision-making guidance in emergency ACS management.
Does ticagrelor reduce cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in the emergency treatment of patients with acute coronary syndromes?
Does ticagrelor reduce cardiovascular death, myocardial infarction, and stroke compared to clopidogrel in the emergency treatment of patients with acute coronary syndromes?
This comprehensive clinical review synthesizes landmark trials and current guidelines demonstrating that ticagrelor reduces major adverse cardiovascular events and all-cause mortality over clopidogrel in ACS, while supporting individualized de-escalation or extended regimens based on ischemic-hemorrhagic risk.
Answers are grounded in this paper and cite their sources.
Supports ticagrelor preference in ACS per guidelines; leaves open optimal de-escalation and extended regimens by ischemic-bleeding risk.
INTRODUCTION/OBJECTIVE: Acute Coronary Syndromes (ACS) - encompassing STEMI and NSTEACS - remain among the foremost causes of cardiovascular mortality worldwide. Ticagrelor, the first reversibly binding, direct-acting oral P2Y12 antagonist, has demonstrated superior efficacy over clopidogrel in landmark trials and carries a Class I recommendation in current international guidelines. This review provides a comprehensive, evidence-based appraisal of ticagrelor's pharmacology, clinical efficacy, safety, and decision- making guidance in the emergency management of ACS. METHODS: PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, and Web of Science were searched from January 2005 to May 2026. A narrative synthesis prioritised meta-analyses, systematic reviews, and randomised controlled trials, including PLATO, ISAR-REACT 5, TWILIGHT, TICO, PEGASUS-TIMI 54, and GLOBAL LEADERS, alongside the 2023 ESC and 2025 ACC/AHA guidelines. RESULTS: Ticagrelor significantly reduced cardiovascular death, myocardial infarction, and stroke versus clopidogrel (HR 0.84; p < 0.001) with a concomitant all-cause mortality benefit. Ticagrelor monotherapy after short dual antiplatelet therapy reduced major bleeding without increasing ischaemic events. Extended ticagrelor (60 mg twice daily) beyond 12 months reduced recurrent events in high-risk post-myocardial infarction patients. Plaque erosion pathobiology and neutrophil extracellular trap attenuation identify contexts in which ticagrelor may confer additional benefit. DISCUSSION: Regimen selection requires integrating the culprit lesion phenotype, a two-axis ischaemichaemorrhagic risk framework, and an assessment of contraindications, drug interactions, and special populations, including elderly patients, those with renal impairment, and those requiring oral anticoagulation. CONCLUSION: Ticagrelor offers potent, reversible platelet inhibition with a favourable efficacy-safety balance across the ACS spectrum. Individualised, phenotype-guided therapy optimises outcomes and minimises harm.
No takes yet. Share an insight, caveat, or question.
Akman et al. (2026) conducted a review in Acute Coronary Syndromes (ACS), including STEMI and NSTEACS, and high-risk post-myocardial infarction. Ticagrelor (including standard dual antiplatelet therapy, monotherapy after short DAPT, and extended 60 mg twice daily beyond 12 months) vs. Clopidogrel was evaluated on Composite of cardiovascular death, myocardial infarction, and stroke (HR 0.84, p=< 0.001). Ticagrelor reduced cardiovascular death, myocardial infarction, and stroke compared with clopidogrel in ACS.
Synapse has enriched 10 related papers. Consider them for comparative context: